Blood and plasma substitutes--plasma expansion and oxygen transport properties.
- 1 August 1985
- journal article
- review article
- Vol. 143 (2) , 202-6
Abstract
Because of the risks and costs of blood and blood product infusion, developing blood and plasma substitutes is of significance. Two currently utilized substances, dextran and hydroxyethyl starch, are effective colloid plasma expanders. The dextrans have properties that improve microcirculatory blood flow but are associated with several possible adverse effects. Hydroxyethyl starch is a well-tolerated agent that has efficacy similar to albumin but at a lower cost. Two newer substances, perfluorocarbons and stroma-free hemoglobin, are being developed to improve oxygen transport as well as plasma expansion.This publication has 54 references indexed in Scilit:
- Pulmonary complications after Fluosol administration to patients with life-threatening blood lossCritical Care Medicine, 1985
- Hypotensive reaction after infusion of a perfluorochemical emulsionCritical Care Medicine, 1984
- Statistical evaluation of plasma substitutes based on 10 variablesCritical Care Medicine, 1982
- The Preoperative Treatment of Severely Anemic Patients with a Perfluorochemical Oxygen-Transport Fluid, Fluosol-DANew England Journal of Medicine, 1982
- Hemoglobin solutions as oxygen-delivering resuscitation fluidsCritical Care Medicine, 1982
- The Priming of Extracorporeal Circuits: The Effect on Canine Blood ElementsTransfusion, 1979
- Anaphylactoid Reaction to Dextran—A Report of 133 CasesActa Anaesthesiologica Scandinavica, 1977
- Low molecular weight dextran: a continuing cause of acute renal failure.BMJ, 1976
- Low Molecular Weight Dextran and Matching by Enzyme TechnicsTransfusion, 1971
- The Effect of Dextran on Platelet Factor 3 Activity: In Vitro and In Vivo StudiesTransfusion, 1965